7 High-Growth Stocks Under $10

The cannabis sector continues to be a tough trade. However, this industry is likely to show significant growth in the coming years, and there will be some consolidation. Therefore, the best buying model applies here and leads to Green Thumb Industries Inc. (OTCMKTS: GTBIF). The company supplies both medical use and recreational cannabis in areas of the United States in which cannabis is legal.  

According to analyst firms such as Statista and Grand View Research, growth in the cannabis market is expected to triple that of beer and tobacco on a percentage basis. Nevertheless, this is a sector that faces significant headwinds due to marijuana’s continued classification as a Schedule 1 drug. This will continue to make it challenging for companies like Green Thumb to get the funding they need. 

However, analysts continue to be bullish on GTBIF stock, which, as of this writing, has a consensus price target of $16.10, which would be a 138% gain.  

In many cases, investors can find stocks that are trading under $10 but have traded significantly above that level before. And if that previous stock price was based on solid fundamentals, stocks like KION GROUP AG (OTCMKTS: KIGRY) can be attractive values. 

KION GROUP provides industrial trucks (e.g., forklifts), integrated automation technologies, and software solutions for optimizing supply chains. This includes but is not limited to, intelligent software, conveyor systems, sorters, automated guided vehicle systems, and automated warehouse systems. Investors may know the company better through its portfolio of brands, which include Dematic, Linde, and Still.  

The company’s fundamentals are solid, and its increasing free cash flow is helping to reduce its debt, which it says is now down to where it was before its last capital raise in 2020.  

After dropping about 20% in 2024, KIGRY stock is up 26.9% in 2025 as of February 19. One analyst gave the stock a price of 50 Euros (approximately $52), which would be an increase of over 400%.  

Denison Mines Corp. (NYSEAMERICAN: DNN) is a Canadian-based uranium miner. The company’s flagship project is its Wheeler River project, which covers 300,000 hectares in the Athabasca Basin region in northern Saskatchewan.  

Uranium will be critical to powering nuclear reactors, drawing increased attention as a clean energy source that can handle the 24/7 demands created by AI data centers.  

Despite the steady drop in uranium prices in 2024, DNN stock was performing well, particularly in the run-up to the November presidential election in the United States. However, DNN stock dropped sharply in December 2024 as a consequence of the broader technology sector drop. It fell further after the launch of China’s open-source large language model (LLM) DeepSeek, causing investors to question the long-term demand for data centers.  

Nevertheless, AI's long-term story is still intact. That’s reflected in the analyst forecasts, which have a $3 price target that would offer investors an 89.2% increase in the stock price.  

Hudbay Minerals Inc. (NYSE: HBM) is another mining stock that offers the possibility of long-term gains. The company’s primary focus is copper mining, but it also mines for a range of precious metals, including gold, silver and molybdenum. The company’s flagship project is its Constancia mine in southern Peru. 

The company generates 89% of its revenue from gold and copper. That creates an intriguing setup for investors. Gold, which accounts for about 27% of revenue was the best performing precious metal in 2024, not to mention one of the best overall asset classes. On the other hand, copper, which accounts for 62% of revenue was the laggard among metals with year-over-year gains of around 5%.  

Gold is expected to continue to shine in 2025, but it’s copper that is expected to see the strongest growth between 2025 and 2030. That explains why analysts are bullish on HBM stock and, as of February 2025, have assigned a consensus price target of $10.93, which is a 46.5% gain from its price on February 19, 2025.  

Small-cap biopharmaceutical companies like Anavex Life Sciences, Inc. (NASDAQ: AVXL) are always about balancing risk and reward. Like many of these companies, Anavex is not only unprofitable; it is still in the pre-revenue stage. 

However, there’s a reason why analysts have a consensus price target of $44, a 411% gain from the stock’s price on February 19, 2025. The company’s lead drug candidate is ANAVEX 2-73, which is being tested for the treatment of Alzheimer’s disease, Parkinson’s disease and other diseases of the central nervous system.  

If successful, the drug would undoubtedly be a blockbuster. To that end, the stock started to soar in December 2024 when the company announced that the European Medicines Agency (EMA) accepted its application to review ANAVEX 2-73. It’s not the same as getting FDA approval in the United States, but for many traders, it was enough to push the stock higher. 

The risk is that the EMA will not approve the application. But if it does, AVXL stock is likely to move significantly higher. Analysts seem to believe this as they maintain their price targets for the stock.  

Vestas Wind Systems A/S (OTCMKTS: VWDRY) is a contrarian play for investors looking for growth stocks trading for less than $10. The Danish company designs, manufactures, installs, and services wind turbines in the United States, Denmark, and other countries.  

VWDRY stock has been dropping since October 2024, largely due to expectations of less demand for wind systems in the Trump administration. However, the company’s most recent earnings report noted a record-high order backlog, which it expects to drive increased revenue in 2025. There is some risk that could change. However, there’s an equally strong chance that lower regulatory barriers would increase demand for power projects of all types, especially those in the United States.  

Investors should note that, unlike many companies in this category, Vestas is a large-cap company covered by over two dozen analysts. They have a consensus price target of $40.50 on VWDRY stock, a whopping increase of over 800%.  

Patient investors with a time horizon beyond 2025 may be intrigued by the sell-off in Aspen Aerogels Inc. (NYSE: ASPN). The company provides industrial insulation primarily used for lithium-ion batteries, which puts it squarely in the electric vehicle (EV) space. And that’s where things have been problematic for investors. 

ASPN was part of the meme stock trade in 2021 and shot up to over $30 per share on expectations that the EV transition was imminent. That transition is ongoing for sure, but demand is slowing for a number of reasons, and it’s unlikely to heat up in 2025. As evidence of that, the company announced a construction halt on a plant in Georgia that was being built to help the company deliver at scale, which doesn’t appear to be an immediate concern.  

That's reflected in the company’s revenue and earnings guidance for 2025, which is coming in flat. But if you have a time horizon beyond that, you may want to consider starting a position now. ASPN stock is trying to form a bottom as it approaches 18-month lows.  

However, if you have the patience to wait on ASPN, analysts give the stock a consensus price target of $16, which represents an 89.5% gain from its price on February 19, 2025.   

It may seem that buying stocks under $10 in search of high growth is an example of FOMO. However, most successful investors in this space are able to keep their emotions in check and look at the stock that is trading at a discount to its fundamentals.  

One of the best ways to decide if a stock may be undervalued is to look at analysts' ratings. While analysts can and do get it wrong sometimes. More often than not their insights into a company are often accurate based on the company's fundamentals and the guidance provided by the company itself.  

That doesn't mean stocks can't move contrary to analysts' forecasts. The meme stock movement continues to prove that. It also doesn't mean that a company is always accurate in its guidance. But more often than many investors would care to admit, following analyst sentiment is a good indicator of a stock's future movement.